Aldeyra Therapeutics, Inc.
ALDX Nasdaq· Pharmaceutical Preparations
Last close · Oct 23, 2026
$0.65
KIRA · Stoqly’s AI analyst, in plain words
- Aldeyra Therapeutics, Inc. lost $33.8M in fiscal 2025.
- Aldeyra Therapeutics, Inc. has $54.7M more cash than debt.
Market cap
$39.2M
P/E
—
Revenue
—
Net income
−$33.8M
Free cash flow
—
Operating margin
—
Aldeyra Therapeutics, Inc. in 30 seconds · fiscal 2025
Does it make a profit?
−$33.8M
No. It lost money last year.
How healthy are the accounts?
2 / 7
Weak. It passes 2 of 7 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Aldeyra Therapeutics, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 27, 2026
- Legal name
- Aldeyra Therapeutics, Inc.
- CIK
- 0001341235
Aldeyra Therapeutics, Inc. · ALDX
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Net income | −$57.8M | −$62.0M | −$37.5M | −$55.9M | −$33.8M |
| Diluted EPS | −$1.07 | −$1.06 | −$0.64 | −$0.94 | −$0.56 |
| Cash | |||||
| Cash from operations | −$42.6M | −$56.6M | −$30.3M | −$43.2M | −$33.3M |
| Capital expenditure | $0.0M | $0.0M | $0.0M | — | — |
| Free cash flow | −$42.6M | −$56.7M | −$30.3M | — | — |
| Share count change | 59.1% | 8.1% | 0.9% | 0.9% | 1.0% |
| Debt and strength | |||||
| Cash and short-term investments | $230M | $174M | $143M | $101M | $70.0M |
| Debt incl. finance leases | $16.0M | $16.3M | $15.3M | $15.3M | $15.3M |
| Shareholders' equity | $206M | $151M | $120M | $71.0M | $44.3M |
| Current ratio | 19.8x | 11.8x | 6.6x | 5.6x | 2.6x |
| Interest coverage | −32.3x | −37.0x | −20.7x | −31.2x | −18.5x |
| Returns and quality | |||||
| Return on equity | −43.6% | −34.8% | −27.7% | −58.5% | −58.7% |
| Return on tangible equity | −28.1% | −41.1% | −31.3% | −78.7% | −76.5% |
| Piotroski F-score | 4 | 1 | 2 | 1 | 2 |
| Altman Z'' | 8.4 | 2.5 | −0.6 | −10.3 | −19.5 |
Insiders bought, 12 months
$0.5M
3 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Aldeyra Therapeutics, Inc. · ALDX
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $0.65 a share, the company is worth $39.2M.
Source: SEC EDGAR XBRL filings (CIK 0001341235). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.